Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR

Giancarlo Fatobene, Vanderson Rocha, Andrew St. Martin, Mehdi Hamadani, Stephen Robinson, Asad Bashey, Ariane Boumendil, Claudio Brunstein, Luca Castagna, Alida Dominietto, Hervé Finel, Yves Chalandon, Chantal Kenzey, Mohamed Kharfan-Dabaja, Hélène Labussière-Wallet, Jose M. Moraleda, Rocco Pastano, Miguel Angel Perales, Hanadi Rafii El Ayoubi, Annalisa RuggeriAnna Sureda, Fernanda Volt, Ibrahim Yakoub-Agha, Mei Jie Zhang, Eliane Gluckman, Silvia Montoto, Mary Eapen

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

PURPOSE To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing non-myeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation. PATIENTS AND METHODS We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide. RESULTS Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; P = .001; and HR, 1.59; P = .005, respectively). Similarly, progression-free survival was lower after UCB transplantations compared with haploidentical bone marrow and peripheral-blood transplantations (HR, 1.44; P = .002; and HR, 1.86; P, .0001), respectively. The 4-year overall and progression-free survival rates after UCB transplantation were 49% and 36%, respectively, compared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after peripheral-blood transplantation, respectively. Lower survival was attributed to higher transplantation-related mortality after UCB transplantation compared with haploidentical bone marrow and peripheral-blood transplantation (HR, 1.91; P = .0001; and HR, 2.27; P = .0002, respectively). CONCLUSION When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.

Original languageEnglish (US)
Pages (from-to)1518-1526
Number of pages9
JournalJournal of Clinical Oncology
Volume38
Issue number14
DOIs
StatePublished - 2020

Bibliographical note

Funding Information:
The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement No. 5U24-CA076518 (M.E.) from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant No. 5U10HL069294 from NHLBI and NCI; Contract No. HHSH250201200016C with the Health Resources and Services Administration (Department of Health and Human Services); and Grants No. N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research.

Publisher Copyright:
© 2020 by American Society of Clinical Oncology

Fingerprint

Dive into the research topics of 'Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR'. Together they form a unique fingerprint.

Cite this